CONTENTS

SPECIAL SECTION ON DRUG METABOLISM AND REGULATION

Editorial. Xiao-bo Zhong and Yurong Lai ........................ 998

Perspective of the Induction of Liver Microsomal Cytochrome P450s by Chemical Compounds. Tsuneo Omura ......................... 1000

Searching for Constitutive Androstane Receptor Modulators. Paavo Honkakoski ........................................ 1002

Clinical Relevance of the Constitutive Androstane Receptor. Sydney Stern, Ritika Kurian, and Hongbing Wang ....................... 1010

Distinct Roles of the Sister Nuclear Receptors PXR and CAR in Liver Cancer Development. Kouichi Yoshinari and Ryota Shizu .................................. 1019

From Steroid and Drug Metabolism to Glycobiology, Using Sulfotransferase Structures to Understand and Tailor Function. Lars C. Pedersen, MyeongJin Yi, Lee G. Pedersen, and Andrea M. Kaminiski .................................................. 1027

ARTICLES

Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses. Zheng Yang, Surendran Rajendran, Vanessa Spires, Brian Poirson, MuraliGarurajan, Zheng Lin, Jaren Arbanas, Stanley Krystek, James Loy, Yuan Cheng, Stephen Carl, Samantha Pace, Yun Wang, John Mehl, Shihua Xu, Krishna Vasudevan, Miranda Broz, Lois Lehman-McKeeman, Paul Morin, and Robert F. Graziano .................................................. 989

Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays. Jocelyn Yabut, Robert Houle, Shubing Wang, Andy Liow, Ravi Katwaru, Hannah Collier, Lucinda Hittle, and Xiaoyan Chu. .................................................. 909

The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro. Natalia Mast, Anna Fotinich, and Irina A. Pikuleva ......................... 923

Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A. Lloyd Wei Tat Tang, Jiexin Fu, Siew Kwan Koh, Guoyi Wu, Lei Zhou, and Eric Chun Yong Chan ................................. 931

Regulation of Blood-Brain Barrier Transporters by Transforming Growth Factor-β/Activin Receptor-Like Kinase 1 Signaling: Relevance to the Brain Disposition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (i.e., Statins). Robert D. Betterton, Wazir Abdullahi, Erica I. Williams, Jeffrey J. Lochhead, HrvojeBrzica, Joshua Stanton, Elizabeth Redell, Chidinma Ogbonnaya, Thomas P. Davis, and Patrick T. Ronaldson ................................. 942


Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models. Yuli Qian and John S. Markowitz .................................................. 968

Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model. Philip Sanda0val, Bei-Ching Chiuang, Lawrence Cohen, Tomoki Yoneyama, Sandeepraj Pasalkar, Robert W. Yucha, Swapu0 K Chowdhury, and Paresh P. Chotiner .................................................. 980